- Home
- WFCF vs BTAI Comparison
WFCF vs BTAI Comparison
Compare WFCF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFCF | BTAI |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 49.2M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WFCF | BTAI |
|---|---|---|
| Price | $12.54 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 3.7K | ★ 669.3K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.82 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $25,512,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $544.99 |
| P/E Ratio | $24.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.26 | $1.17 |
| 52 Week High | $13.78 | $9.26 |
Technical Indicators
Market Signals| Indicator | WFCF | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 52.95 |
| Support Level | $11.23 | $1.82 |
| Resistance Level | $13.15 | $2.33 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 80.21 | 71.93 |
Price Performance
Historical ComparisonAbout WFCF Where Food Comes From Inc.
Where Food Comes From Inc is a third-party food verification company. It offers food production audits and uses verification processes to ensure that claims made by food producers and processors are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. The company operates in two segments that are verification and certification and Software Sales and Related Consulting. It generates the majority of its revenue from verification and certification.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.